Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Astex Sued by Shareholder Over $886 Million Otsuka Bid

Astex Pharmaceuticals Inc. was sued by an investor seeking more money for his shares in a planned $886 million takeover by Otsuka Holdings Co.

Astex, a cancer-drug maker based in Dublin, California, said Sept. 5 it agreed to be bought by Tokyo-based Otsuka for $8.50 a share, a 27 percent premium at the time.

“The proposed transaction is the product of a flawed process” and the shares “could be worth double what they’re selling for right now,” Astex investor Stephen Bushansky said in a complaint made public today in Delaware Chancery Court in Wilmington.

The shares fell 2 percent to $8.58 in Nasdaq Stock Market trading at 2:52 p.m. in New York.

Bushansky asks a judge to halt the buyout and rule that Astex directors violated their duty to get the best possible price.

The company said in an e-mailed statement that the lawsuit is entirely without merit.

Otsuka, which makes the mood-stabilizing drug Abilify, would gain a potential cancer-drug pipeline in the deal. Astex markets Dacogen for leukemia and has another leukemia drug under clinical trial.

The case is Bushansky v. Astex, CA8896, Delaware Chancery Court (Wilmington).

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.